Trial · NCT00595413
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | Placebo | 46.1 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | Atacicept 150 mg With Loading Dose | 44.9 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | Atacicept 150 mg Without Loading Dose | 57.7 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | Adalimumab | 70.9 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | Placebo | 14.5 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | Atacicept 150 mg With Loading Dose | 29.5 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | Atacicept 150 mg Without Loading Dose | 33.3 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | Adalimumab | 38.0 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | Placebo | 5.3 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | Atacicept 150 mg With Loading Dose | 12.8 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | Atacicept 150 mg Without Loading Dose | 12.8 | percentage of participants | ||
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | Adalimumab | 17.7 | percentage of participants | ||
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26 | Placebo | 59.2 | percentage of participants | ||
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26 | Atacicept 150 mg With Loading Dose | 64.1 | percentage of participants | ||
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26 | Atacicept 150 mg Without Loading Dose | 67.9 | percentage of participants | ||
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26 | Adalimumab | 81.0 | percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs | Placebo | TEAEs | 38 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs | Atacicept 150 mg With Loading Dose | TEAEs | 49 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs | Atacicept 150 mg Without Loading Dose | TEAEs | 49 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs | Adalimumab | TEAEs | 50 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00595413/results